https://010261.iqanda-cme.com/ 2020-02-12T19:51:01+0000 weekly 1 https://010261.iqanda-cme.com/about-fabry-disease 2021-02-18T20:42:49+0000 weekly 0.8 https://010261.iqanda-cme.com/fabry-disease 2020-11-20T03:43:37+0000 weekly 0.8 https://010261.iqanda-cme.com/fabry-disease-resources-and-trials 2020-02-20T19:23:31+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/why-is-it-important-to-recognize-the-neurological-manifestations-of-fd-what-advantages-accrue-to-the-patient-from-early-diagnosis-in-which-target-organs-affected-by-fd-can-we-potentially-ameliorate-disease-progression 2020-02-24T19:52:58+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-can-dermatologists-do-to-raise-awareness-of-fd-and-ensure-the-diagnosis-is-confirmed 2020-02-20T16:43:10+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/given-the-heterogeneity-of-symptoms-gi-pain-acroparesthesias-and-neurological-that-herald-the-onset-of-fd-what-counsel-can-you-give-clinicians-to-test-for-fd-and/or-distinguish-fabry-from-other-conditions-that-make-early-diagnosis-challe 2020-02-20T16:57:26+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-rationale-for-disciplined-surveillance-systems-for-fd-patients-with-either-asymptomatic-cv-or-those-in-whom-the-diagnosis-has-been-confirmed 2020-02-20T16:54:52+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/other-than-ert-and-chaperone-therapy-what-other-pharmacologic-interventions-are-effective-and-safe-for-treating-the-gi-symptoms-of-fd 2020-02-20T16:17:49+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/based-on-registry-data-for-fabry-disease-what-have-we-learned-about-the-importance-of-gi-symptoms-including-gender-based-differences-in-the-context-of-improving-awareness-of-fd-as-a-condition-for-which-we-should-screen 2020-02-20T16:05:39+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-pathophysiology-of-the-angiokeratomas-and-telangiectasias-seen-in-fd-what-is-the-typical-distribution-of-these-lesions-in-male-versus-female-patients-and-with-what-other-conditions-might-these-be-confused 2020-02-20T17:01:36+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-provide-a-synopsis-of-the-inheritance-patterns-of-fabry-disease-the-penetrance-of-target-organ-manifestations-and-symptomatology-in-men-vs-women-and-the-diagnostic-implications-of-the-heterogeneity-of-this-fabry 2020-02-20T16:56:37+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-exactly-are-the-symptomatic-age-of-onset-and-enzymatic-activity-criteria-that-discriminate-between-so-called-classical-vs-non-classical-fabry-disease-and-is-there-a-further-delineation-of-these-two-groups-based-on-gender 2020-02-20T16:32:57+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-your-systematic-step-by-step-diagnostic-work-up-for-a-young/adolescent-male-in-whom-the-diagnosis-of-fd-must-be-considered-and/or-ruled-out-what-genetic-tests-should-be-performed 2020-02-20T16:28:41+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-category-of-mutation-one-that-is-associated-with-some-degree-of-production-of-the-alpha-galactosidase-a-a-gal-a-enzyme-is-amenable-to-the-fda-approved-oral-chaperone-therapy-migalastat 2020-02-20T16:35:08+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/after-the-diagnosis-of-fd-has-been-confirmed-and-genetic-mutational-signatures-have-been-generated-and-enzyme-activity-levels-measured-at-what-age-can-available-therapies-be-started-and-how-long-should-patients-be-treated 2020-02-20T16:38:29+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/how-often-is-cryptogenic-stroke-or-early-onset-stroke-a-marker-of-fabry-disease-in-the-young-adult-population-and-what-is-the-etiology-of-this-neurological-manifestation 2020-02-24T19:49:36+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-provide-a-roadmap-for-a-disciplined-approach-for-detecting-screening-and-diagnosing-patients-who-present-with-specific-findings-family-history-and/or-a-clinical-phenotype-hypertrophic-cardiomyopathy-in-particular-suggestive-of-fd 2020-02-20T16:26:07+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/why-is-it-important-to-make-the-diagnosis-of-fd-what-therapeutic-action-steps-can-be-taken-if-the-diagnosis-is-confirmed-what-role-can-the-dermatologist-play-in-preventing-more-significant-target-organ-involvement 2020-02-20T16:34:44+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-summarize-the-central-importance-of-the-neurological-symptoms-findings-and-complications-of-fd 2020-02-24T19:50:16+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-focus-on-the-earliest-age-group-in-which-gi-symptoms-of-fd-can-plausibly-be-detected 2020-02-20T16:07:30+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-are-the-characteristic-angiokeratoma-skin-lesions-and-dermatologic-hallmarks-associated-with-fabry-disease-fd-at-what-age-do-they-present-in-what-distribution-with-what-other-conditions-might-they-be-confused-in-the-differential-dia 2020-02-20T16:59:23+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/how-often-are-the-dermatologic-manifestations-of-fd-the-portal-of-entry-into-the-diagnosis-of-this-condition-and-what-is-the-role-of-the-dermatologist-for-ensuring-the-diagnosis-of-fd-is-made-as-early-as-possible 2020-02-20T16:50:43+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/to-whom-should-patients-with-confirmed-fd-be-referred-what-is-the-ideal-way-to-follow-these-patients-and-what-is-the-role-of-the-clinical-geneticist-is-a-multi-disciplinary-approach-preferred 2020-02-20T16:40:30+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-have-long-term-registries-taught-us-about-the-effects-of-treatment-on-mitigating-risk-and/or-progression-of-target-organ-deterioration-in-particular-of-cardiac-disease-need-for-kidney-replacement-and/or-stroke-in-patients-with-fd 2020-02-20T16:36:26+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/how-do-the-cv-manifestations-of-fd-disease-change-and/or-present-during-adolescence-and-what-is-the-role-of-cardiac-mri-in-this-age-group-and-how-does-it-help-you-identify-the-fd-phenotype 2020-02-20T16:24:31+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-are-the-key-diagnostic-parameters-specifically-urinary-and-related-renal-biomarkers-including-albuminuria-and-creatine-that-should-increase-awareness-of-and-prompt-evaluation-and-further-genetic-testing-for-fabry-disease 2020-02-20T16:27:33+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/is-there-a-relationship-between-gb3-levels-and-renal-fabry-disease-and-what-is-the-relationship-between-gb3-levels-in-the-classic-variant-of-fd 2020-02-20T16:29:01+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-guidance-can-you-give-your-cardiologist-colleagues-to-enhance-detection-patients-with-fd-what-collateral-co-morbidities-should-be-investigated-and-how-is-your-management-strategy-changed-if-the-diagnosis-of-fd-is-confirmed 2020-02-20T16:26:27+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-share-with-as-an-example-of-a-patient-who-was-ultimately-diagnosed-with-fabry-disease-on-the-basis-of-neurological-symptoms-and-why-the-diagnosis-was-almost-missed-initially-as-it-so-often-is-in-childhood-and-adolescents 2020-02-24T19:55:46+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-surveillance-strategies-in-the-context-of-cardiovascular-disease-optimize-early-detection-assessment-and-monitoring-of-patients-with-suspected-or-confirmed-fd 2020-02-20T17:04:37+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-neuropathobiology-of-alpha-galactosidase-a-deficiency-and-how-does-this-enzyme-deficiency-produce-these-heterogeneous-neurological-symptoms 2020-02-24T19:55:13+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/why-is-it-important-the-mandate-in-fact-to-diagnose-fd-and-what-is-the-current-evidence-and/or-expert-consensus-about-the-use-of-either-chaperone-therapy-with-migalastat-or-ert-to-mitigate-progression-of-fd-in-the-kidney-and-in-other-tar 2020-02-20T16:30:27+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-discuss-a-specific-adult-patient-who-came-to-you-with-gi-symptoms-and-confirmed-fabry-disease-in-whom-therapeutic-intervention-improved-their-gi-manifestations-and-quality-of-life 2020-02-20T16:51:14+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-differential-diagnosis-of-the-angiokeratomas-and-telangiectasias-that-are-characteristic-of-fd-with-what-other-conditions-might-these-lesions-be-confused 2020-02-20T16:52:56+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-underlying-pathobiology-of-this-lysosomal-disorder-and-how-does-the-presentation-differ-in-men-and-women 2020-02-20T16:34:24+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/at-what-age-can-fd-consistent-gi-manifestations-first-emerge-what-is-the-most-frequent-misdiagnosis-of-gi-symptoms-that-in-retrospect-were-the-first-signs-of-fd-in-an-individual-patient 2020-02-20T16:07:14+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-are-the-initial-neurological-manifestations-of-fabry-disease-as-they-present-in-childhood-and-adolescence 2020-02-24T19:54:10+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-your-systematic-line-of-inquiry-and-evaluation-strategy-for-diagnosing-fabry-disease-both-in-patients-who-present-with-the-classical-constellation-of-symptoms-as-well-as-those-who-present-in-a-more-nuanced-non-specific-manner 2020-02-20T16:31:39+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/if-a-clinician-wishes-to-confirm-the-diagnosis-of-fd-what-is-the-systematic-roadmap-to-ensure-the-appropriate-biomarkers-and-genetic-information-have-been-obtained-with-enzymatic-activity-and/or-genetic-sequencing-tests 2020-02-20T16:33:17+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-specific-additional-testing-enzyme-activity-levels-and/or-genetic-mutational-assessment-is-required-in-patients-who-present-with-neurologic-symptoms-characteristic-of-fabry-disease 2020-02-24T19:50:53+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-other-corroborative-manifestations-and-familial-historical-features-of-fd-should-clinicians-inquire-about-to-solidify-their-suspicion-for-the-diagnosis 2020-02-20T16:31:57+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/at-what-point-in-the-natural-history-of-fd-do-the-dermatologic-manifestations-of-fd-appear-do-they-tend-to-appear-prior-or-after-other-collateral-manifestations-gi-symptoms-or-acroparesthesias 2020-02-20T16:59:40+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/how-does-the-pathophysiology-of-fabry-as-a-lysosomal-disorder-produce-the-wide-range-of-cv-manifestations-that-should-alert-physicians-to-suspect-fd-as-an-underlying-cause-for-unexplained-symptoms-in-men-and-women 2020-02-20T16:54:20+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-discuss-the-diagnostic-and-clinical-importance-of-lymphedema-as-a-manifestation-of-fd-what-is-the-etiology-of-lymphedema-in-fd 2020-02-20T16:40:51+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-percentage-of-patients-with-fd-actually-have-dermatologic-manifestations 2020-02-20T16:53:28+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/if-initial-genetic-tests-or-the-clinical-picture-proteinuria-family-history-no-evidence-of-diabetes-suggest-fd-what-is-the-next-level-of-diagnostic-genetic-tests-i-e-mutational-testing-that-should-be-performed 2020-02-20T16:44:12+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-summarize-the-pathophysiology-and-pathobiology-of-renal-impairment-and-associated-findings-in-particular-albuminuria-on-renal-function-testing-in-the-setting-of-fabry-disease 2020-02-20T17:02:51+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/how-do-the-presentations-of-fabry-disease-differ-in-men-and-women-and-what-are-the-implications-for-how-the-disease-should-be-treated-in-each-gender 2020-02-20T16:38:51+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/are-there-prospective-studies-that-in-fact-are-designed-to-evaluate-the-effects-of-currently-approved-chaperone-and-ert-based-treatments-for-fd-on-the-progression-of-cv-complications-of-fd 2020-02-20T16:23:08+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/since-a-heterogeneous-range-of-gi-symptomatology-is-associated-with-fabry-disease-can-you-discuss-the-spectrum-of-symptoms-that-are-encountered 2020-02-20T16:41:19+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/how-often-are-gi-symptoms-the-portal-for-entertaining-and-confirming-the-diagnosis-of-fd 2020-02-20T16:41:47+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/given-the-availability-of-new-agents-to-treat-fd-and-a-growing-body-of-evidence-that-enzyme-focused-treatment-might-mitigate-progression-what-is-the-rationale-for-suspecting-and-confirming-the-diagnosis-of-fd 2020-02-20T16:35:41+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-specific-symptom-related-issues-especially-late-complications-of-fd-such-as-stroke-are-being-assessed-in-relation-to-impact-of-therapy-on-disease-progression 2020-02-20T16:37:43+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/do-all-patients-with-fd-have-the-same-propensity-to-develop-fabry-renal-disease-and-how-does-the-male/female-incidence-discordance-help-us-make-the-diagnosis 2020-02-20T16:29:22+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-summarize-the-current-guidelines-and/or-recommendations-from-europe-and-the-u-s-for-diagnostic-evaluation-and-treatment-of-fd 2020-02-20T16:30:52+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-are-the-ophthalmologic-findings-of-fd-and-how-are-they-temporally-related-to-the-dermatologic-manifestations-of-fd 2020-02-20T16:42:46+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/to-improve-awareness-suspicion-and-diagnostic-accuracy-for-fabry-disease-can-you-discuss-the-expected-manifestations-of-fd-based-on-gender-and-age-and-how-do-the-clinical-phenotypes-and-symptoms-segregate-among-different-patient-subgroup 2020-02-20T16:49:33+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/how-does-deficiency-of-the-lysosomal-enzyme-alpha-galactosidase-a-lead-to-gi-symptoms-what-is-the-gi-related-pathobiology-of-fabry-disease-through-what-vascular-tissue-and-neuropaths-mechanisms-does-gl-3-accumulation-cause-gi-symptoms 2020-02-20T16:06:10+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-are-the-cv-manifestations-of-fd-disease-in-the-adult-population-and-how-does-the-triad-of-arrhythmias-early-mi-and/or-cardiomyopathy-set-into-motion-diagnostic-tests-and-surveillance-strategies-to-evaluate-the-presence-of-fd 2020-02-20T16:24:49+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-spectrum-of-cardiovascular-manifestations-of-fd-what-is-the-age-of-onset-why-is-it-important-that-we-recognize-the-cardiovascular-clinical-phenotypes-arrhythmias-hypertrophic-cardiomyopathy-stroke-etc-of-fd 2020-02-20T17:05:28+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-discuss-some-of-the-less-well-appreciated-manifestations-of-fabry-disease-vestibular-dysfunction-hearing-loss-and-autonomic-dysfunction-and-how-their-presence-can-aid-in-making-the-diagnosis-of-fabry-disease 2020-02-24T19:51:27+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/in-patients-with-fd-how-do-you-use-genetic-testing-and-results-of-enzyme-activity-levels-of-alpha-galactosidase-a-a-gal-a-to-determine-whether-oral-chaperone-therapy-with-migalastat-vs-iv-ert-is-best-suited-for-an-individual-patient 2020-02-20T19:37:37+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/how-early-in-childhood-are-the-renal-manifestations-present-in-classic-fabry-in-males-what-is-the-natural-history-of-renal-dysfunction-and-what-specific-metrics-related-to-albuminuria/proteinuria-should-be-followed-and-increase-suspicion 2020-02-20T17:07:00+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-natural-history-of-fd-dermatologic-lesions-over-time-do-the-angiokeratomas-and-telangiectasias-evolve-change-distribution-or-regress-over-time-what-is-the-differential-diagnosis-what-does-a-biopsy-show 2020-02-20T16:52:40+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-role-of-lysosomal-and-extralysosomal-globotriaosylceramide-gb3-accumulations-in-the-pathology-including-as-soluble-circulating-mediators-of-renal-disease-in-fd 2020-02-20T17:03:19+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-are-the-specific-gi-symptoms-encountered-in-patients-with-fd-and-what-specific-symptom-patterns-should-alert-the-clinician-that-fd-should-be-excluded-in-the-differential-diagnosis 2020-02-20T16:06:34+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-underlying-cause-of-the-failure-to-diagnose-syndrome-as-it-relates-to-classical-fabry-disease 2020-02-20T16:39:23+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/why-is-confirmatory-genetic-testing-mandatory-for-helping-clinicians-identify-therapeutic-agents-that-are-best-suited-for-an-individual-patient-and-to-determine-whether-a-mutation-is-amenable-to-chaperone-therapy 2020-02-24T19:52:06+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/if-fd-disease-is-diagnosed-by-a-dermatologist-during-childhood-or-adolescence-what-is-the-therapeutic/management/referral-roadmap-in-this-patient-population-how-do-you-approach-the-multi-disciplinary-nature-of-this-condition 2020-02-20T16:53:49+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/once-you-determine-that-a-male-or-female-patient-s-symptoms-and/or-physical-manifestations-are-consistent-with-a-diagnosis-of-fabry-disease-what-disciplined-systematic-approach-to-you-use-to-genetic-mutational-testing 2020-02-20T16:32:34+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/why-do-the-heterogeneous-neurological-manifestations-make-the-diagnosis-extremely-challenging-do-all-patients-with-fd-either-present-with-or-eventually-develop-such-neurological-symptoms-as-acroparesthesias 2020-02-24T19:56:01+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/with-respect-to-screening-for-fd-in-the-pediatric-age-group-what-features-of-the-family-history-should-be-elicited-in-order-to-guide-the-diagnostic-evaluation-including-enzyme-activity-levels-and-genetic-testing 2020-02-20T16:42:16+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-pattern-of-progression-of-neurological-symptoms-of-fabry-disease 2020-02-24T19:55:28+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/although-gi-and-dermatologic-manifestations-tend-to-dominate-the-clinical-phenotype-of-fd-in-childhood-are-there-cardiovascular-manifestations-i-e-arrhythmias-in-this-subgroup-that-might-point-to-the-disease 2020-02-20T16:55:08+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/given-the-new-therapies-including-chaperone-therapy-with-migalastat-and-ert-available-for-fd-why-do-you-believe-there-should-be-a-call-to-action-among-the-cv-community-that-would-heighten-awareness-of-this-disease 2020-02-20T16:54:37+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/because-many-of-the-symptoms-complaints-and-manifestations-of-fd-can-overlap-with-other-conditions-in-what-age-groups-should-the-clinician-be-alert-for-the-patterns-you-describe-in-order-to-improve-detection-and-mutational-testing-for-fa 2020-02-20T16:49:54+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/is-there-evidence-that-treatment-of-fabry-disease-either-with-migalastat-based-chaperone-therapy-or-ert-is-capable-of-mitigating-progression-of-gi-symptoms 2020-02-20T16:07:50+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/there-is-sometimes-a-preconception-that-women-who-are-carriers-for-fd-do-not-suffer-from-cv-complications-and-the-diagnosis-is-missed-or-delayed-with-adverse-consequences-can-you-elaborate-on-this 2020-02-20T16:25:09+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/are-there-registry-or-prospective-trial-data-showing-that-early-treatment-of-fd-improves-clinical-outcomes-how-well-do-the-dots-connect 2020-02-20T16:36:03+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/when-you-encounter-angiokeratomas-that-you-think-are-characteristic-of-fd-what-is-your-next-step-in-the-diagnostic-process-do-you-routinely-biopsy-the-lesions-what-are-the-characteristic-findings-and-do-you-do-genetic-testing 2020-02-20T16:53:13+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-construct-a-diagnostic-roadmap-including-family-history-symptom-complexes-and/or-biomarker-manifestations-for-the-nephrologist-that-will-optimize-detection-of-fd-at-the-front-lines-of-practice 2020-02-20T16:28:19+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-other-target-organs-should-be-evaluated-to-corroborate-the-diagnosis-what-is-the-pathologic-march-of-fd-and-what-is-the-sequence-of-target-organ-deterioration-in-males-with-classic-disease-vs-females 2020-02-20T16:30:02+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/can-you-provide-a-real-world-example-of-a-patient-and-associated-family-members-with-fabry-disease-that-you-have-treated-and-that-illustrates-the-clinical-decision-tree-that-traces-the-journey-from-mutational-testing-to-selection-of-opti 2020-02-20T16:34:02+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-are-the-challenges-of-diagnosing-non-classical-fabry-disease-in-the-adult-population-what-is-the-importance-of-testing-all-patients-with-unexplained-progressive-renal-disease-and-hypertrophic-cardiomyopathy 2020-02-20T16:40:07+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/how-do-the-neurological-symptoms-of-classical-fd-present-in-male-vs-female-populations-and-what-other-concurrent-symptoms-should-the-clinician-inquire-about-to-corroborate-the-diagnosis 2020-02-24T19:54:54+0000 weekly 0.8 https://010261.iqanda-cme.com/videos/what-is-the-differential-diagnosis-of-the-non-specific-gi-symptoms-reported-by-patients-with-fd-and-what-entities-must-be-systematically-excluded-as-part-of-the-work-up-for-the-non-specific-manifestations-of-fd 2020-02-20T16:06:55+0000 weekly 0.8 https://010261.iqanda-cme.com/courses/the-iqanda-fabry-disease-diagnostic-intelligence-zone 2023-04-14T03:34:17+0000 weekly 0.8